Endymed Ltd (ENDY.TA)
ILA 320.1
(0.0%)
ILA 320.1
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.53 Million USD | -31.88% |
| 2022 | 2.24 Million USD | -29.76% |
| 2021 | 3.2 Million USD | 290.01% |
| 2020 | 821 Thousand USD | -62.61% |
| 2019 | 2.19 Million USD | -1.74% |
| 2018 | 2.26 Million ILS | 186.33% |
| 2017 | -2.45 Million ILS | 14.13% |
| 2016 | -2.81 Million ILS | 0.03% |
| 2015 | -3.01 Million USD | -143.42% |
| 2014 | -1.23 Million USD | -17600.0% |
| 2013 | -7000.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 44 Thousand USD | 108.68% |
| 2024 Q1 | -507 Thousand USD | -307.79% |
| 2023 Q2 | 392 Thousand USD | -66.21% |
| 2023 Q1 | 1.16 Million USD | 85.6% |
| 2023 Q4 | 244 Thousand USD | 192.42% |
| 2023 Q3 | -264 Thousand USD | -167.35% |
| 2023 FY | - USD | -31.88% |
| 2022 Q3 | -52 Thousand USD | -108.61% |
| 2022 FY | - USD | -29.76% |
| 2022 Q4 | 625 Thousand USD | 1301.92% |
| 2022 Q2 | 604 Thousand USD | -43.66% |
| 2022 Q1 | 1.07 Million USD | 778.69% |
| 2021 Q4 | 122 Thousand USD | -86.15% |
| 2021 Q1 | 918 Thousand USD | 408.59% |
| 2021 Q2 | 1.28 Million USD | 39.54% |
| 2021 FY | - USD | 290.01% |
| 2021 Q3 | 881 Thousand USD | -31.23% |
| 2020 Q3 | -3167.00 USD | -100.84% |
| 2020 Q1 | 376.5 Thousand USD | -42.25% |
| 2020 Q2 | 376.5 Thousand USD | 0.0% |
| 2020 Q4 | 180.5 Thousand USD | 5799.4% |
| 2020 FY | - USD | -62.61% |
| 2019 Q2 | 886 Thousand ILS | 214.18% |
| 2019 Q3 | 375 Thousand ILS | -57.67% |
| 2019 FY | - USD | -1.74% |
| 2019 Q4 | 652 Thousand USD | 73.87% |
| 2019 Q1 | 282 Thousand ILS | -46.79% |
| 2018 Q1 | 604 Thousand ILS | 147.04% |
| 2018 FY | - ILS | 186.33% |
| 2018 Q4 | 530 Thousand ILS | 2.91% |
| 2018 Q3 | 515 Thousand ILS | -17.07% |
| 2018 Q2 | 621 Thousand ILS | 2.81% |
| 2017 Q2 | -186 Thousand USD | 72.65% |
| 2017 Q3 | -333 Thousand USD | -79.03% |
| 2017 Q4 | -1.28 Million USD | -285.59% |
| 2017 FY | - ILS | 14.13% |
| 2017 Q1 | -680 Thousand USD | 21.11% |
| 2016 Q2 | -821 Thousand USD | 27.09% |
| 2016 Q3 | 79 Thousand USD | 109.62% |
| 2016 FY | - ILS | 0.03% |
| 2016 Q4 | -862 Thousand USD | -1191.14% |
| 2016 Q1 | -1.12 Million USD | 12.51% |
| 2015 FY | - USD | -143.42% |
| 2015 Q4 | -1.28 Million USD | -54.87% |
| 2015 Q3 | -831 Thousand USD | -198.92% |
| 2015 Q2 | -278 Thousand USD | 55.23% |
| 2015 Q1 | -621 Thousand USD | -31.57% |
| 2014 Q2 | -255 Thousand USD | -13.84% |
| 2014 Q1 | -224 Thousand USD | 0.16% |
| 2014 FY | - USD | -17600.0% |
| 2014 Q4 | -472 Thousand USD | -112.61% |
| 2014 Q3 | -222 Thousand USD | 12.94% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | -47.03 Thousand USD | 58.88% |
| 2013 Q3 | 226.85 Thousand USD | 582.35% |
| 2013 Q4 | -224.36 Thousand USD | -198.9% |
| 2013 Q1 | -114.36 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|